Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer.

Muthusamy S, Andersson S, Kim HJ, Butler R, Waage L, Bergerheim U, Gustafsson JÅ.

Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20090-4. doi: 10.1073/pnas.1117772108. Epub 2011 Nov 23.

2.

Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.

Klomp JA, Petillo D, Niemi NM, Dykema KJ, Chen J, Yang XJ, Sääf A, Zickert P, Aly M, Bergerheim U, Nordenskjöld M, Gad S, Giraud S, Denoux Y, Yonneau L, Méjean A, Vasiliu V, Richard S, MacKeigan JP, Teh BT, Furge KA.

BMC Med Genomics. 2010 Dec 16;3:59. doi: 10.1186/1755-8794-3-59.

3.

Molecular cytogenetic characterization shows higher genetic homogeneity in conventional renal cell carcinoma compared to other kidney cancers.

Alimov A, Sundelin B, Bergerheim U, Pavlenko M, Pisa P, Zetterberg A, Larsson C, Lagercrantz S.

Int J Oncol. 2004 Oct;25(4):955-60.

PMID:
15375545
4.

Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival.

Alimov A, Sundelin B, Wang N, Larsson C, Bergerheim U.

Int J Oncol. 2004 Jul;25(1):179-85.

PMID:
15202004
5.

Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR.

Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6. Epub 2004 Jan 7.

6.

The role of chromosome 8p22 deletion for predicting disease progression and pathological staging in prostate cancer.

Matsuyama H, Pan Y, Oba K, Yoshihiro S, Matsuda K, Hägarth L, Kudren D, Naito K, Bergerheim US, Ekman P.

Aktuelle Urol. 2003 Jul;34(4):247-9.

PMID:
14566675
7.

Difference between Swedish and Japanese men in the association between AR CAG repeats and prostate cancer suggesting a susceptibility-modifying locus overlapping the androgen receptor gene.

Li C, Grönberg H, Matsuyama H, Weber G, Nordenskjöld M, Naito K, Bergh A, Bergerheim U, Damber JE, Larsson C, Ekman P.

Int J Mol Med. 2003 Apr;11(4):529-33.

PMID:
12632109
8.

Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer.

Matsuyama H, Pan Y, Yoshihiro S, Kudren D, Naito K, Bergerheim US, Ekman P.

Prostate. 2003 Feb 1;54(2):103-11.

PMID:
12497583
9.

Clinical and genetic studies of Birt-Hogg-Dubé syndrome.

Khoo SK, Giraud S, Kahnoski K, Chen J, Motorna O, Nickolov R, Binet O, Lambert D, Friedel J, Lévy R, Ferlicot S, Wolkenstein P, Hammel P, Bergerheim U, Hedblad MA, Bradley M, Teh BT, Nordenskjöld M, Richard S.

J Med Genet. 2002 Dec;39(12):906-12. Erratum in: J Med Genet. 2003 Feb;40(2):150..

10.

Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade.

Mahdy E, Pan Y, Wang N, Malmström PU, Ekman P, Bergerheim U.

Anticancer Res. 2001 Sep-Oct;21(5):3167-73.

PMID:
11848469
11.

Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer.

Matsuyama H, Pan Y, Oba K, Yoshihiro S, Matsuda K, Hägarth L, Kudren D, Naito K, Bergerheim US, Ekman P.

Clin Cancer Res. 2001 Oct;7(10):3139-43.

12.

Characterization of chromosomal abnormalities in uroepithelial carcinomas by G-banding, spectral karyotyping and FISH analysis.

Fadl-Elmula I, Kytölä S, Pan Y, Lui WO, Derienzo G, Forsberg L, Mandahl N, Gorunova L, Bergerheim US, Heim S, Larsson C.

Int J Cancer. 2001 Jun 15;92(6):824-31.

13.

Precancerous lesions in the kidney.

Van Poppel H, Nilsson S, Algaba F, Bergerheim U, Dal Cin P, Fleming S, Hellsten S, Kirkali Z, Klotz L, Lindblad P, Ljungberg B, Mulders P, Roskams T, Ross RK, Walker C, Wersäll P.

Scand J Urol Nephrol Suppl. 2000;(205):136-65. Review.

PMID:
11144893
14.

5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines.

Pan Y, Lui WO, Nupponen N, Larsson C, Isola J, Visakorpi T, Bergerheim US, Kytölä S.

Genes Chromosomes Cancer. 2001 Feb;30(2):187-95.

PMID:
11135436
15.

Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma.

Alimov A, Kost-Alimova M, Liu J, Li C, Bergerheim U, Imreh S, Klein G, Zabarovsky ER.

Oncogene. 2000 Mar 9;19(11):1392-9.

16.

Chromosomal numerical aberrations detected by fluorescence in situ hybridization on bladder washings from patients with bladder cancer.

Marano A, Pan Y, Li C, Pagliarulo A, Elmberger G, Tribukait B, Ekman P, Bergerheim U.

Eur Urol. 2000 Mar;37(3):358-65.

PMID:
10720866
17.

Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.

Pan Y, Kytölä S, Farnebo F, Wang N, Lui WO, Nupponen N, Isola J, Visakorpi T, Bergerheim US, Larsson C.

Cytogenet Cell Genet. 1999;87(3-4):225-32.

PMID:
10702678
18.

Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma.

Alimov A, Li C, Gizatullin R, Fredriksson V, Sundelin B, Klein G, Zabarovsky E, Bergerheim U.

Anticancer Res. 1999 Sep-Oct;19(5B):3841-6.

PMID:
10628321
19.

Distinct deleted regions on chromosome segment 16q23-24 associated with metastases in prostate cancer.

Li C, Berx G, Larsson C, Auer G, Aspenblad U, Pan Y, Sundelin B, Ekman P, Nordenskjöld M, van Roy F, Bergerheim US.

Genes Chromosomes Cancer. 1999 Mar;24(3):175-82.

PMID:
10451696
20.

Links between genetic and environmental factors and prostate cancer risk.

Ekman P, Grönberg H, Matsuyama H, Kivineva M, Bergerheim US, Li C.

Prostate. 1999 Jun 1;39(4):262-8.

PMID:
10344215

Supplemental Content

Loading ...
Support Center